FDA Fast Tracks AG-221 to Treat AML
the Cancer Therapy Advisor take:
Agios Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has designated AG-221, which is currently undergoing clinical trials, Fast Track status for the treatment of acute myelogenous leukemia (AML) with a positive isocitrate dehydrogenase-2 (IDH2) mutation.
AG-221 is an orally available, selective, potent inhibitor of the IDH2 mutation. Agios Pharmaceuticals initiated a phase 1 multicenter, open-label, dose escalation clinical study of AG-221 to evaluate the safety and tolerability of the drug. IDH2 is an important enzyme utilized during the Krebs cycle, but in many cancers, the enzyme appears to be mutated. By blocking this enzyme in cancer cells, the cancer cells would be destroyed.
The FDA designates certain drugs Fast Track status in order to speed up development and the review of new drugs so that they may be made available to patients sooner. The FDA reserves this designation for medications that treat serious or life-threatening diseases or to fill an unmet medical need.
AML is a type of cancer in which the bone marrow makes abnormal myeloblasts, erythrocytes, or thrombocytes. The disease is known for its rapid disease progression and is the most common form of acute leukemia in adults.
The FDA has granted Fast Track designation to AG-221, a first-in-classinhibitor, to treat AML.
Currently, AG-221 is being evaluated in a Phase I clinical trial in patients with advanced hematologic malignancies. Agios chief medical officer Dr Chris Bowden said the company believes this designation is an important recognition by the FDA of the nonclinical and clinical data reported to date and the potential for AG-221 to address a significant unmet need for patients diagnosed with AML.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML